ROS1, RET Now Available in Liquid Biopsy Test
The test provides highly sensitive results in 72 hours for non-small cell lung cancer patients.
Read More
Search Results for: lung cancer
Company to Commercialize Proteomic Blood Test in China
The partners will also collaborate on the development of new mass spectrometry-based assays in oncology and other clinical areas.
Read More
Owlstone Medical Nets Millions in Investment Round
The funds will finance the commercial launch of breath biomarker research and development services and clinical trials in lung and colon cancer screening.
Read More
Campaign Highlights Comprehensive Genomic Testing to Advance Precision Medicine in Lung Cancer
The campaign is focused on empowering patients with lung cancer and their caregivers to initiate a dialogue with their physicians about comprehensive genomic testing and its potential to expand treatment options for the patient.
Read MoreStudy Identifies NSCLC Patients Who Are More Likely to Have Improved Progression-Free Survival on Third-Generation EGFR-TKI Therapy
The blood-based proteomic test helps identify non-small cell lung cancer patients for epidermal growth factor receptor tyrosine kinase inhibitor therapy.
Read More